Efficacy and Safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients With Amyotrophic Lateral Sclerosis (Study MT ‐1186‐ A02 )
Muscle & Nerve · 2025
DOI: 10.1002/mus.28448 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Muscle & Nerve, 2025. Verfasst von Jeffrey Rothstein und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Edaravone, Free Radical Scavengers. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Mitsubishi Tanabe Pharma America Inc..
Abstract (Originalsprache)
Introduction/Aims An On/Off dosing regimen of intravenous (IV) edaravone and edaravone oral suspension is approved in the US for the treatment of amyotrophic lateral sclerosis (ALS). Placebo‐controlled clinical trials showed IV edaravone slows the rate of physical functional decline. This study evaluated whether investigational daily dosing displayed superior efficacy vs. approved on/off dosing of edaravone oral suspension, and assessed safety and tolerability, over 48 weeks in patients with ALS.
Methods
Study MT‐1186‐A02 (NCT04569084) was a multicenter, phase 3b, double‐blind, parallel group, superiority study that randomized patients to edaravone oral suspension (105‐mg dose) administered Once Daily or the same edaravone oral suspension dose administered according to the approved On/Off regimen including placebo to mimic daily drug dosing. Patients had definite or probable ALS, baseline forced vital capacity ≥ 70%, and baseline disease duration ≤ 2 years. The primary endpoint was a combined assessment of function and survival (CAFS) at week 48, which included change in ALS Functional Rating Scale‐Revised (ALSFRS‐R) and time to death.
Results
CAFS at week 48 indicated Once Daily dosing did not show a statistically significant difference vs. approved on/off dosing ( p = 0.777). Both dosing regimens provided comparable change from baseline ALSFRS‐R total score to week 48 (least squares mean difference: 0.27 [95% CI −1.43 to 1.97]). Edaravone oral suspension was well tolerated, and no new safety concerns were identified in either group.
Discussion
Daily edaravone oral suspension did not show superiority and had equivalent safety and tolerability vs. the approved On/Off regimen, reinforcing the appropriateness of the approved dosing regimen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
- Montreal Neurological Institute and Hospital, Montreal, Canada.
- Woodland Research Northwest, Rogers, Arkansas, USA.
- Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
- McMaster University Health Sciences Centre, Hamilton, Ontario, Canada.
- Università Degli Studi di Torino, Centro Regionale Esperto per la Sclerosi Laterale Amiotrofica (CRESLA), Turino, Italy.
ORCID-Profile: Fumihiro Takahashi, Stephen Apple
Förderung
- Mitsubishi Tanabe Pharma America Inc.
Zitieren
APA
Rothstein, J., Genge, A., De Silva, S., Zinman, L., Chum, M., Chio, A., Sobue, G., Aoki, M., Yoshino, H., Doyu, M., Selness, D., Todorovic, V., Sasson, N., Hirai, M., Takahashi, F., Salah, A., Wamil, A., & Apple, S. (2025). Efficacy and Safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients With Amyotrophic Lateral Sclerosis (Study MT ‐1186‐ A02 ). Muscle & Nerve. https://doi.org/10.1002/mus.28448
Vancouver
Rothstein J, Genge A, De Silva S, Zinman L, Chum M, Chio A, et al. Efficacy and Safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients With Amyotrophic Lateral Sclerosis (Study MT ‐1186‐ A02 ). Muscle & Nerve. 2025. doi:10.1002/mus.28448
BibTeX
@article{Rothstein2025,
author = {Rothstein, Jeffrey and Genge, Angela and De Silva, Shari and Zinman, Lorne and Chum, Marvin and Chio, Adriano and Sobue, Gen and Aoki, Masashi and Yoshino, Hiide and Doyu, Manabu and Selness, Daniel and Todorovic, Vesna and Sasson, Nissim and Hirai, Manabu and Takahashi, Fumihiro and Salah, Alejandro and Wamil, Art and Apple, Stephen},
title = {Efficacy and Safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients With Amyotrophic Lateral Sclerosis (Study MT ‐1186‐ A02 )},
journal = {Muscle & Nerve},
year = {2025},
doi = {10.1002/mus.28448}
}
EUVIMED